PCSK9 inhibitors × cardiovascular events

TrialCirculation2022

Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.

Michelle L O'Donoghue et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 6,635 people · 2022

Randomised comparison

Reduced cardiovascular events

−15%−25% to −4%

Bigger than 3 in 10 for cardiovascular events

As reported

HR 0.85, 95% CI 0.75–0.96

One number in the abstract

the abstract, start to end

revascularization (hazard ratio, 0.85 [95% CI, 0.75-0.96];

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
HR 0.850.75–0.96
PCSK9 inhibitorsCardiovascular events
1 / 3

192 papers cite itlatest 60 shown

2022
2023
2024
2025
2026
this paperpooled ittrialcites it

3 trials

Full record →Abstract, authors, funding and every citing paper · PMID 36031810